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1. Introduction 
Cycloablation is a destructive procedure used to decrease the intra-ocular pressure (IOP) 
trough the ablation of the ciliary body that produces aqueous humour. Many destructive 
techniques, including diathermy, cryotherapy, ultrasounds, beta irradiation, and laser 
photocoagulation have been employed with a wide range of results and side effects. 
Although all above techniques can effectively destroy the ciliary body, only few of them 
have been used widely enough to convincingly demonstate their clinical usefulness and 
gain general acceptance. The ideal method of cyclodestruction should produce clinically 
useful and predictable reduction of intraocular pressure (IOP), with minimal complications  
and side effects. (Bartamian & Higginbotham, 2001). Ideally it should have a wide 
therapeutic window between insufficient and too aggressive treatment intensity, that can 
result in either insufficient IOP reduction or hypotony/phtisis. Cyclodestructive procedures 
are usually reserved for cases of glaucoma in eyes with little or no visual potential that 
proved refractory to medical treatment and outflow surgeries. (Lin, 2008) As an exception to 
this long established indication, cyclodestructive procedures performed with the 810 nm 
infrared diode laser transscleral cyclophotocoagulation have been successfully applied  
also in eyes with refractory glaucoma and good visual potential (Rotchford et al., 2010; 
Wilensky & Kammer, 2004) supporting an emerging notion that the indications for 
transscleral laser cyclophotocoagulation should not be limited to eyes with poor visual 
acuity or potential.  
2. Background 
Coagulation or destruction of the ciliary body to reduce aqueous production has been 
advocated in the treatment of glaucoma since the 1930s with the introduction of penetrating 
cyclodiathermy (Voght et al., 1936). In the 1950s, cyclocryotherapy was proven reasonably 
safe and effective to reduce IOP with less tissue destruction and better predictability 
compared to cyclodiathermy (Bietti, 1950). Problems still existed, however, including intense 
postoperative pain, intraocular pressure (IOP) rise, marked inflammation, hemorrhage, and 
a significant incidence of hypotony and visual loss. Ciliary ablation with ultrasounds was 
also briefly utilized, but it was eventually abandoned because of marked scleral thinning 
and ectasia at the treatment site (Coleman at al., 1985).  
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2.1 Laser cyclophotocoagulation 
Laser cyclophotocoagulation has become the principal surgical method for reducing 
aqueous production. The first laser transscleral cyclophotocoagulation (TSCPC) was 
described by Beckam and Sugar in the early 1970s. Initially, they used the 694 nm ruby laser, 
but later reported that the 1064 nm infrared Neodymium : Yttrium-Aluminium-Garnet laser 
(Nd : YAG) was more effective due to its superior transmission through the sclera and 
absorption by the ciliary epithelium. The delivery of laser energy to the ciliary processes 
through the sclera may be performed either with an indenting contact probe or a noncontact 
projected beam. The development of the compact, portable 810 nm I.R. ophthalmic diode 
laser has made it more convenient to perform contact TSCPC. The same 810 nm I.R. diode 
laser beam can also be delivered inside the eye through an endoscope to directly 
photocoagulate the ciliary body under endoscopic guidance. This technique, named 
endoscopic cyclophotocoagulation (ECP), has become an increasingly important weapon in 
the glaucoma surgeon’s armamentarium for the treatment of refractory glaucoma at the time 
of ocular surgery and may have some distinct advantages over the transscleral approach in 
eyes with visual potential. In 1976, Merritt described his method of transpupillary 
cyclophotocoagulation of the ciliary processes under indirect visualization via a gonioscopic 
laser lens. This interesting approach, potentially safer than the more invasive ECP, did not 
become popular because of the difficulty in visualizing and treating the ciliary processes 
through the gonio-lens, but it may still represent a good option for aniridic eyes. 
Laser cyclo-destructive procedures can be divided as follows:  
• Transpupillary CPC 
• Transvitreal endophotocoagulation 
• Transscleral CPC 
• Noncontact and contact 1064 nm Nd:YAG laser 
• Contact 810 nm diode laser 
• Endoscopic 810 nm diode laser CPC 
In the United States, CPC is used predominantly for refractory glaucoma difficult to control 
with conventional glaucoma filtration, such as neovascular glaucoma, traumatic glaucoma, 
glaucoma in aphakic eyes, advanced developmental glaucoma, inflammatory glaucoma, 
glaucoma associated with corneal transplantation, silicone oil-induced glaucoma, and 
glaucoma in eyes with conjunctival scarring from previous surgery. Cyclophotocoagulation 
is also used in eyes with limited visual potential, in urgent situations with dangerously 
elevated IOP, or for pain relief in eyes with no visual potential. It has uncommonly been 
used in patients who are not candidates for conventional glaucoma therapy due to poor 
compliance with care or poor postoperative follow-up. Cyclophotocoagulation has also been 
evaluated for use as primary surgical treatment in developing countries where conventional 
glaucoma therapy is not available (Egbert 2001). 
3. Description of the various CPC procedures 
3.1 Transpupillary cyclophotocoagulation 
Direct transpupillary treatment of the ciliary processes with the argon laser (488/514 nm) is 
rarely used, because a clear visual axis and a well-dilated pupil are required to enable 
photocoagulation of the entire length of the ciliary processes. Clinical results have been poor 
when treatment was limited to the anterior most portions of the ciliary processes. 
Transpupillary CPC of the ciliary processes, exposed through peripheral iridectomy or a 
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widely dilated pupil, can be effective. The mechanism may be related to a laser-induced 
retraction of the ciliary body. 
3.2 Transvitreal endophotocoagulation 
Transvitreal endophotocoagulation using a visible or infrared laser beam (514 nm argon, 532 
nm solid-state or 810 nm diode) delivered through a vitreo-retinal endoprobe has been used 
with some success when performed in conjunction with a vitrectomy in the operating room. 
It requires clear media, aphakia or pseudophakia to directly treat the ciliary processes 
visible in the field of the operating microscope with scleral indentation. The laser power is 
titrated to produce a visible burn using continuous wave exposure durations that favour 
some thermal spread in the deeper layers of the ciliary processes.  
3.3 Transscleral cyclophotocoagulation (TSCPC) 
Due to the optical properties of the human sclera, TSCPC is performed with infrared 
emitting lasers, most commonly with the 810 nm Diode Laser delivered via a contact probe 
or with the 1064 nm Nd:YAG laser, delivered either with a non-contact projected beam or 
with a contact probe. 
3.4 1064 nm Nd:Yag Laser Non-Contact TSCPC 
Transscleral ciliary body ablation utilizing the Nd:YAG laser at 1064 nm wavelength has the 
theoretical advantage of better transmission through the scleral with less back scatter than 
shorter wavelengths, such as 514 nm argon and 810 nm diode lasers. Non-contact TSCPC 
was performed using the Nd:YAG laser in the free-running thermal mode (Microruptor III 
Lasag, Thun, Switzerland, no longer commercially available) for a duration of 20 msec, and 
the defocus setting number, which offsets the focal point of the 1064 nm infrared treating 
beam 3.6 mm posteriorly to the focal point of the red aiming beam. In this way, when the 
red aiming beam is focused on the conjunctiva, the infrared treatment beam is focused 3.6 
mm below, supposedly within the ciliary processes. The laser energy is adjusted from 5 to 8 
Joules (J) per application. Retrobulbar or peribulbar anaesthesia is given, and the patient is 
seated at the laser slit lamp. The treatment is directed parallel to the visual axis, focusing the 
aiming beam on the sclera, 1.5 mm posterior to the limbus, superiorly and inferiorly, and 1.0 
mm posterior to the limbus nasally and temporally. A contact lens with 1.0 mm markings 
parallel to the limbus can be used to facilitate the placing of the applications, to hold the 
eyelids open and to bleach the conjunctiva. Alternatively, a lid speculum can be used to 
open the eyelids, and the red aiming beam can be focused on the centre of a 3 mm slit beam. 
Approximately eight to ten applications per quadrant are placed from 270 to 360 degrees. 
Treatment may be reduced to 180 degrees in patients judged to be clinically at risk for 
hypotony (Pastor et al., 2001). 
3.5 1064 nm Nd:Yag Laser Contact TSCPC 
Retrobulbar or peribulbar anaesthesia is given, the patient lies supine, and a eyelid 
speculum is placed. The anterior edge of the 2.2 mm sapphire tip of the delivery fibre optic 
handpiece (Surgical Laser Technologies, Inc., Malvern, PA) is placed 0.5 to 1.0 mm posterior 
to the limbus (the probe is centred 1.5 to 2.0 mm posterior to the limbus). Gentle pressure is 
applied with the probe, which is oriented perpendicular to the sclera. The laser energy 
setting is 5 to 9 Joules, for a duration of 0.7 seconds, with approximately eight spots per  
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quadrant placed from 270 to 360 degrees. After the procedure, atropine and dexamethasone 
ointments are applied and the eye is patched. The patch may be removed in the evening and 
anti-glaucoma drops should be reinstituted. Prostaglandin analogues may be excluded in 
the short term if cystoid macular edema (CME) is a concern, and cholinergics should be 
temporarily discontinued to avoid increased anterior segment inflammation. Postoperative 
prednisolone acetate 1% is applied 4 times daily for 10 to 14 days and tapered according to 
inflammation (Lin, 2008). 
3.6 810 nm Diode Laser Contact TSCPC 
It is performed using a semiconductor diode laser system (IRIS Oculight SLx, IRIDEX Corp., 
Mountain View, CA), its 810 nm wavelength exhibits lower scleral transmission (35%) but 
considerably greater absorption by melanin than the 1064 nm wavelength. The laser energy 
is transmitted through a 600 μm diameter quartz fiber with a spherical protruding tip 
oriented by the footplate of the hand-piece called “G-Probe”. Positioning the G-Probe 
parallel to the optical visual axis with the shorter edge of the footplate next to the anterior 
border of the limbus will centre the fibre optic tip 1.0-1.2 mm posterior to the corneoscleral 
limbus and direct the energy toward the ciliary processes. The tip protrudes 0.7 mm beyond 
the footplate contact surface, which indents the conjunctiva and sclera to enhance the 
transmission of the laser energy. The probe footplate is curved spherically to match the 
scleral curvature. Maximum settings from the system are 3.0 watts power and 9.9 seconds 
duration. Retrobulbar or peribulbar anesthesia is given and a lid speculum is placed. 
Duration is set at 2000 ms (2 seconds), and the initial power setting is 1750 mW. The power 
is increased in 250 mW increments to a maximum of 2500mW until an audible “pop” 
(caused by tissue explosion of the ciliary process, the iris root anteriorly or the retina 
posteriorly) is heard, then the power is reduced by 250 mW and treatment is completed at 
this power. Some surgeons recommend lower power and longer burn duration, for example 
1250 mW at 4 seconds (5.0 Joules) in heavily pigmented eyes and 1500 mW at 3.5 seconds in 
lightly pigmented eyes (5.25 Joules). Six applications per quadrant are typically placed over 
270 degrees involving the inferior, nasal and superior quadrants for a total of 18 applications 
per treatment. This is based on burns spaced half the width of the G-Probe footplate (2 mm), 
but various reports have used from 18 to 40 spots, with 180 to 360 degrees for the initial 
treatment (Pastor et al., 2001). Generally, the incidence of retreatment increases when a 
lower energy and/or a lower number of spots are applied. With all non-contact or contact 
TSCPC procedures, the outcome predictability is limited by the inability to visualize treated 
tissue. In lieu of direct visualization, trans-illumination may be used to identify the location 
of the ciliary body, especially in eyes with abnormal anatomy or in enlarged eyes 
(congenital glaucoma). An ocular trans-illuminator is placed against the posterior globe and 
directed towards the ciliary sulcus. In a darkened room, the diffuse illumination will 
demarcate the ciliary body, which can be marked externally (Sharkey & Murray, 1994). 
3.7 810 nm diode laser endoscopic cyclophotocoagulation (ECP) 
The laser unit for ECP (Endo Optiks, Little Silver, NJ) incorporates 1) a diode laser that emits 
810 nm continuous-wave energy, 2) a 175W Xenon light source, 3) a Helium-Neon laser 
aiming beam, and 4) a video imaging and recording camera. All 4 optical elements are 
transmitted through a 18-gauge or 20-gauge fibre-optic probe, which is inserted into the eye. 
The optimal focus for the laser is 0.75 mm from the probe tip, and the endoscope provides a 
70-degree field of view. The main unit is compact and portable with a maximum power 
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output of 2.0 W. The laser power and the exposure duration (up to 9.99 seconds) are 
adjustable with the controls in the console. The foot pedal controls the laser firing, with the 
actual duration of each application determined by the exposure duration setting or by the 
pedal depression, whichever ends first. The 2 main approaches to reach the ciliary processes 
are via a limbal or a pars plana entry. The limbal approach is preferred to avoid the anterior 
vitrectomy and the associated risks for choroidal and retinal detachment. However, certain 
cases are more safely treated through the pars plana, for example, aphakic eyes with 
posterior synechiae limiting the access to the ciliary sulcus. In both situations, a retrobulbar 
block with lidocaine and bupivicaine is performed or general anaesthesia can be considered 
in selective cases. In the limbal approach, after dilation of the pupil with cyclopentolate 1% 
and phenylephrine 2.5%, a paracentesis is created and the anterior chamber is filled with 
viscoelastic agent, which is further used to expand the nasal posterior sulcus. This 
viscoelastic expansion of the posterior chamber allows for easier approach to the pars plicata 
with the ECP probe. A 2.2-mm keratome is then used to enter into the anterior chamber at 
the temporal limbus. After orientation of the probe image outside of the eye, the 18-gauge or 
20-gauge endoprobe is inserted through the incision into the posterior sulcus. At this time, 
the ciliary processes are viewed on the monitor and treatment can begin. The laser is set at 
continuous-wave and power settings are 300 to 900 mW. Approximately a 180-degree span 
of ciliary processes is photocoagulated (more area can be treated if a curved probe is used). 
Laser energy is applied to each process until shrinkage and whitening occur. The ciliary 
processes are treated individually or in a ‘‘painting’’ fashion across multiple processes. If 
excessive energy is used, the process explodes with a ‘‘pop’’ sound due to bubble formation, 
leading to excessive inflammation and breakdown of the blood-aqueous barrier. After the 
nasal 180 degrees of ciliary processes are treated, a separate incision is created at the nasal 
limbus in a similar fashion as above. The temporal processes are then photocoagulated for a 
total of up to 360 degrees, if desired. Typically, 180 to 360 degrees are treated. Before closure 
of the wounds, the viscoelastic material is removed from the anterior chamber with 
irrigation and aspiration. In the pars plana approach, an infusion port is inserted through 
the inferior pars plana and 2 superior entries are created for vitrectomy and illumination. 
Only a limited anterior vitrectomy is performed to allow adequate and safe access to all of 
the ciliary processes. The ECP probe can be inserted through each superior entry for 
treatment of the opposite 180 degrees of processes. There may be a few superior processes 
that cannot be accessed because the entry ports are not exactly 180 degrees opposite to each 
other. Laser CPC is carried out with the same parameters and end points as described for 
the limbal approach. If the anterior segment surgeon has not had extensive experience in 
posterior segment surgery, assistance from a retinal surgeon should be sought for the 
establishment of the pars plana entry ports and the limited anterior vitrectomy. Risk of 
inadvertent choroidal and/or retinal detachment is a serious concern and should be 
minimized. In all patients, whether under local or general anaesthesia, retrobulbar 
bupivicaine is administered before or at end of the surgery to minimize postoperative pain. 
Sub-Tenon’s injection of 1mL of triamcinolone (40 mg/mL) is also given for inflammation. 
On postoperative day 1, patients are placed on a regimen of topical antibiotics, steroids, 
nonsteroidal anti-inflammatory agents, cycloplegics, and their preoperative glaucoma 
medications except for miotics and prostaglandin analogues because these may exacerbate 
intraocular inflammation or its sequelae. Antibiotics are discontinued after 1 week, and the 
steroids, nonsteroidal anti-inflammatory agents, and cycloplegics are tapered as 
inflammation subsides. Glaucoma medications are removed according to the intraocular 
pressure (IOP) requirements. Administration of acetazolamide during the evening of 
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surgery may be used to prevent a spike in IOP from underlying glaucoma, inflammation, or 
possible retained viscoelastic (Lin, 2008). 
4. Published results 
It is difficult if not impossible to compare studies that have different entry criteria and 
definitions of success. In fact, “success” in cyclophotocoagulation procedures has been 
defined as achieving IOP < 21 or 22 mmHg, and/or an IOP reduction of 20% or 30%; some 
study considered IOP < 5 mmHg as hypotony and, thus, a failure. Most studies allow the 
postoperative use of medications to achieve this definition of success.  
 
4.1 Transscleral cyclophotocoagulation 
4.1.1 1064 nm Nd:Yag Laser Non-Contact TSCPC 
In a retrospective study, Youn et al. (Youn et al., 1996) reviewed 479 patients in a follow-up 
period of 3-75 months (mean 22 months). The range of laser energy settings was 4 to 8 J. 
Postoperative IOP was between 5 and 20 mmHg in 52% of the patients. Forty percent of the 
patients lost two or more Snellen visual acuity lines. Visual deterioration was significantly 
associated with neovascular glaucoma, African descent, post-treatment hypotony, and more 
than 6 months of follow-up. Phthisis was encountred in 14% of treated patients. Noncontact 
Nd:YAG cyclophotocoagulation enhances the risk of graft failure in patients with previous 
penetrating keratoplasty. In a prospective, unmasked randomized trial, Shields et al. 
(Shields et al., 1993) assigned two groups of 89 patients to two energy settings, 4 J (range 3.7 
to 4.5 J) for the Group A and 8 J (range 7 to 8.5 J) for the Group B, with 30 applications 
utilizing a contact lens. Among the patients who did not require further surgery, better 
success (75% versus 60%) and fewer retreatments (25% versus 40%) were observed in the 
higher energy. Among those patients who received no further surgery, vision loss was 56% 
of patients in Group A (4 J) versus 42% of patients in group B (8 J). There was no significant 
difference between the two groups. Mean follow-up was 12.6 months, ranging from 5 to 20 
months. Delgado et al. (2003) studied the results of Nd:YAG laser non-contact TSCPC on 
neovascular glaucoma. Mean follow-up was 27 months (range 1 – 148), 115 eyes were 
evaluated using 7.8 J energy setting (20 to 40 application over 270 degrees) and the success 
rate was 65%, 49.8% and 34.8% after 1, 3 and 6 years respectively. There were 11.5% phtisis 
and 39.1% eyes had a loss of two or more Snellen visual acuity lines. An interesting 
retrospective study (Ayyala et al., 1998) attempted to compare mitomycin C trabeculectomy, 
glaucoma drainage device (GDD) and Nd:YAG non-contact TSCPC in the glaucoma 
management after penetrating keratoplasty. This was a non-comparative case series with 
fewer than 20 patients in each group. Mean follow-up was 12.9 months. There was no 
statistically significant difference in successful IOP control between mitomycin C 
trabeculectomy (77% success), GDD (80% success), or non-contact TSCPC (63%). There was 
no significant difference in the rate of failure of the corneal graft following trabeculectomy 
(15%), GDD (0%), or TSCPC (17%) that compared fairly with the 11% to 65% failure rate of 
the corneal graft following glaucoma surgery reported in the literature. (Pastor et al., 2001). 
As the criteria for success varied in the different studies, it is not surprising that the rate of 
success spanned from 35% to 83%. The most common complications included the loss of 
two or more Snellen visual acuity lines in up to 40% of patients, phthisis in 0 to 14%, 
hyphema in 0 to 4%, and corneal oedema in 0 to 6% of patients. Sympathetic ophthalmia has 
also been reported as an extremely rare complication. (Bechrakis et al., 1994). 
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LASER 
TYPE 
GLAUCOMA 
F -UP 
(mo) 
N 
(eyes) 
VA 
LOSS 
(%) 
N. 
TREAT 
POWER DEGREES N. 
Delgado et al., 2003 nc YAG neovascular 27 115 39 1,4 7,8 (J) 270 20-40 
Youn et al., 1998 nc YAG all 10,4 46 0 1,13 
5,21 to 7,5 
(J) 
360 32 
Shields et al., 1993 nc YAG all 12 45 26 1 4 (J) 360 
Shields et al., 1993 nc YAG all 12 44 36 1 8 (J) 360 
Youn et al., 1996 nc YAG all 22 479 40 1 6 (J) N/A 
Lin et al., 2004 c YAG all 67 68 16 1,4 7 to 9 (W) 360  32 - 40 
Schuman et al., 
1992 
c YAG all 19 116 31 1,27 7 to 9 (W) N/A 32 - 40 
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4.1.2 1064 nm Nd:Yag laser contact TSCPC 
There are fewer studies (see Table 1) reporting the use of Nd:YAG laser contact TSCPC than 
there are reporting non-contact TSCPC. Schuman et al. (Schuman et al., 1992) reported 
retrospectively on a series of 116 eyes of 114 patients with a mean follow-up of 1 year (range 
6-19 months). Treatment consisted of 32 to 40 applications, for a total of 7 to 9 W of power 
delivered for 0.7 seconds. IOP control of 3 to 22 mmHg was achieved in 65% of eyes. 
Twenty-seven percent were retreated. Hypotony with less than 3 mmHg occurred in nine 
eyes, six of which were phthisical. Nineteen eyes (16%) lost light perception, and 47% of 
eyes with V.A. of 20/200 or better lost two or more Snellen visual acuity lines (17 of 36 eyes). 
Lin et al (Lin et al., 2004) in 2004 reported similar results about a series of 68 eyes with a 
mean follow-up of 5.58 years (range 0.1 – 10 years). Treatment consisted of 32 to 40 
applications, for a total of 7 to 9 watts of power delivered for 0.7 seconds. Intraocular 
pressure control of 3 to 25 mmHg was achieved in 60 % of eyes after one year and in 48% 
after ten years with only one treatment. 40% of patient where retreated, and this has been 
considered a failure. Hypotony less than 3 mmHg was seen in 3 eyes, none of which were 
phthisical. Eleven eyes worsened their visual acuity.  
4.1.3 810 Nm diode laser contact TSCPC 
For a variety of reasons, mainly clinical effectiveness and practicality, 810 nm diode laser 
contact TSCPC has been universally adopted to the point to become the standard of care for 
specific conditions. As a result, there are more publications in the literature on 810nm diode 
TSCPC (see Table 2) than on any other CPC modality, although many of them are only 
retrospective. As indicated in Table 2, the mean number of eyes reported in the studies was 
55.82 (SD =+/- 58.26) (Standard Deviation) eyes with a variety of diagnoses and of laser 
treatment parameters. Laser power ranged from 1.25 to 3 watts (mean 1.94 W) for a mean 
exposure time of 2.16 seconds, for a mean number of applications of 22.10 (SD=+/- 7.02) 
over 180 to 360 degrees, sometimes adjusting the power for pops and sometimes not. Mean 
follow-up was 19.86 months (SD=+/- 12.71). Mean success rate was 67.26% (SD=+/- 15.70), 
but this cannot be a good indicator, because the definition of success was heterogeneous (see 
Table 2). Mean number of medication was 2.52 (SD=+/- 0.63) pre-operatively and 1.62 
(SD=+/- 0.71) post-operatively. Mean loss of visual acuity was 24.74% (SD=+/- 16.78). 
Retreatment rate was 1.48 (SD=+/- 0.45). Complications were, hypotony (0 to 25%), phthisis 
(0 to 11%), AS inflammation (0 to 27%), choroidal detachment (0 to 10%), cataract 
progression (0 to 40%), atonic pupil (0 to 70%) and hyphema (0 to 13%). Rarely reported 
complications were endophthalmitis, failure of corneal graft, CMO, bullous keratopathy, 
band keratopathy, persistent ocular pain. Rarely reported complications included necrotizing 
scleritis (Ganesh et al., 2006), scleral perforation (Kwong at al., 2005), iris retraction and 
retroflexion (Sony et al., 2003) and malignant glaucoma (Azuara-Blanco et al., 1999). Table 2 
stratifies the outcomes among various types of glaucoma. In Neovascular Glaucoma success 
rate ranges from 40% to 64% with a mean follow up from 9 to 60 months; in Silicon Oil 
Glaucoma success rate ranges from 44% to 82% with a mean follow up from 4 to 22 months; 
in Pediatric Glaucoma success rate ranges from 67% to 72% with a mean follow up from 20 
to 21 months; in Chronic Angle Closure Glaucoma (CACG) success rate ranges from 86% to 
92% with a mean follow up from 12 to 26 months; and in Keratoprosthesis Glaucoma 
success rate is 66% with a mean follow up of 26.6 months. 810 nm Diode Laser Contact 
TSCPC has also been used in 49 eyes with a good visual acuity (20/60 or better). 
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 STUDY GLAUCOMA F-UP (mo) 
N 
(eyes) 
N.  
TREAT 
POWER 
(W) 
TIME 
(s) 
DEGREES 
N. 
SPOTS 
Spencer et al., 
1999 
all 21,5 58 1,6 2,00 2 270 14 
Yildirim et al., 
2009 
nv 24 33 1 1,50 2 270 17 
Ghosh et al., 
2010 
nv 9 14 1 2,00 2 180-270 25 
Preussner et 
al., 2010 
africans 6 75 N/A 5,00 0,2 360 20 
Malik et al., 
2006 
all 35 28 2 2,12 2 360 24 
Semchyshyn 
et al., 2002 
all 26,9 21 1,38 2,00 2 270 21,9 
Schlote et al., 
2000 
inflammatory 12 22 2 2,00 2 270 12,5 
Rotchford et 
al., 2010 
good vision 60 49 1,73 2,00 2 N/A 14,4 
Sood et al., 
2009 
pediatric 19,8 9 1 1,25 3,5 180-270 17,4 
Kirwan et al., 
2009 
pediatric 21 77 2,3 1,50 1,5 300 40 
Lai et al., 2002 CACG 12 14 1,14 2,00 2 270 16,3 
Lai et al., 2005 CACG 26,5 13 1,15 2,00 2 270 17,5 
Han et al., 
1999 
silicon oil 12 11 1,18 2,00 2 360 23,5 
Agarwal et 
al., 2004 
all types 15,8 30 1,2 1,50 2 360 40 
Rivier et al., 
2009 
keratoprotesis 26,6 18 1,3 1,87 2 270 17,5 
Noureddin et 
al., 2006 
all 13,69 36 1,25 2,25 2 360 28 
Sivagnanavel 
et al., 2005 
silicone oil 
glaucoma 
21,8 18 1,5 2,00 1,5 180 25 
Egbert et al., 
2001 
all 13,2 40 1,22 1,50 1,5 360 20 
Egbert et al., 
2001 
all 13,2 39 1,22 1,25 2,5 360 20 
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 STUDY GLAUCOMA F-UP (mo) 
N 
(eyes) 
N.  
TREAT 
POWER 
(W) 
TIME 
(s) 
DEGREES 
N. 
SPOTS 
Ansari et al., 
2007 
all 12,5 74 1,01 2,00 2 360 30 
Kaushik et al., 
2008 
all 14,3 66 1,16 2,00 2 270 18 
Nabili et al., 
2004 
diabetic 
neovascular 
glaucoma 
N/A 20 1,45 2,00 2 270 15 
Kramp et al., 
2002 
all 13,9 193 1,3 1,60 2 360 27 
Grueb et al., 
2006 
all 24 90 1,3 2,00 2 180 17,5 
Iliev et al., 
2007 
all 30,1 131 1,54 2,00 2 270 22 
Schlote et al., 
2007 
aphakic and 
posttraumatic 
42 46 2,58 2,00 2 180 20 
Heinz et al., 
2006 
juvenile 
idiopathic 
arthritis 
10,1 21 2,15 2,00 2 180 25 
Ocakoglu et 
al., 2005 
all 11,4 32 1,68 2,50 2 270-300 22 
Murphy et al,. 
2003 
all 17 263 1,5 N/A N/A N/A N/A 
Walland, 1998 all 10,1 22 1 1,50 1,5 360 40 
Walland, 1998 all 11,4 8 1 1,50 1,5 180 20 
Frezzotti et 
al., 2010 
all 17 124 1,26 2,00 2 180-270 15 
Leszcynski et 
al., 2009 
neovascular 60 30 2,4 1,75 N/A 270 17,5 
Raivio et al., 
2008 
all 26 60 1,4 0,43 10 180 20 
Gangwani et 
al., 2010 
silicon oil 4 9 2,34 1,87 2 270 30 
Youn et al., 
1998 
all 10,4 49 1,2 2,37 2 360 24,63 
Brancato et 
al., 1995 
all 20,7 68 N/A 2,60 2 360 18 
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The success rate on pressure reduction (IOP <21) was 90%, but 60% of eyes lost 1 Snellen 
visual acuity line and 30% of the eyes lost more than 2 Snellen visual acuity lines. 810 nm 
Diode Laser Contact TSCPC has been compared to Ahmed Valve implantation by Yildirim 
et al. (Yildirim et al., 2009) who found a success rate of 61% for TSCPC vs. 59% for Ahmed 
Valve with a mean follow up of 24 months. In a similar study Sood et al (Sood et al., 2009) 
compared 810 nm Diode TSCPC to Ahmed Valve implantation in Pediatric Glaucoma and 
found a success rate of 66.7% for TSCPC vs 62.5% for Ahmed Valve with a mean follow up 
of 19.8 and 26.3 months respectively. Malik et al (Malik et al., 2006) compared 810 nm Diode 
TSCPC to Molteno tube shunt and found a success rate of 64% for TSCPC vs 81% for 
Molteno tube shunt with a mean follow up of 35 months. Youn et al (Youn et al., 1998) 
compared non-contact TSCPC with 1064 nm Nd:YAG and 810 nm diode lasers in a 
prospective, randomized, unmasked trial. Mean follow-up was 10.4 months. Success was 
83% and 71% of the YAG and diode patients, respectively, (no statistically significant 
difference). Retreatment in the YAG group was lower (8.7%; 4/46) than the diode group 
(18%; 6/49). Although not statistically significant, the Nd:YAG group had a slightly higher 
success. In clinical practice the 1064 nm Nd:YAG laser in the free-running thermal mode is 
not commercially available anymore and most clinicians have elected to use the more 
compact and user-friendly 810 nm diode laser with the contact G-Probe. Agarwal et al 
(Agarwal et al., 2004) compared the 830 nm Diode Laser contact TSCPC to the 830 nm Diode 
Laser non-contact TSCPC 830 and found a success rate of 94% for Contact vs. 90% for Non-
Contact after a mean follow up of 15.8 months. Although there is not a general agreement, 
most studies have found that the amount of energy used for 810 nm diode laser contact 
TSCPC seems to correlate with treatment success rate, without implying a higher 
complication or vision loss rate.  
4.2 Endoscopic cyclophotocoagulation 
4.2.1 810 Nm diode laser endoscopic cyclophotocoagulation (ECP) 
810 nm diode laser ECP is a relatively new method for CPC, and this is reflected in the 
relatively smaller number of publications (see Table 3). It’s very difficult to compare such 
studies because laser parameters are different or not well specified. In Table 3 we 
summarized six studies that evaluated a 33.3 mean number of patients (SD=+/- 18.3) range 
12 - 68, with various types of glaucoma, including pediatric glaucoma, for a mean follow-up 
of 11.9 months (SD=+/- 5.5) range 4.5-21.3 and with different definition of success. Mean 
success rate was 59.1% (SD=+/- 23.7) range 17-82.9%. Mean pre- and post-operative number 
of medication was 2.2 (SD=+/- 0.5) and 1.5 (SD=+/- 0.5) respectively. Mean visual acuity 
loss of two or more Snellen lines was 9% (SD=+/- 8) range 0-22% and retreatment rate was 
1.16 (SD=+/- 0.2). Complications were hypotony (0 to 8%), phthisis (0 to 3%), anterior 
segment inflammation (0 to 6%), hyphema (0 to 9%), and RD (0 to 8%). In pediatric 
glaucoma (refractory glaucoma with corneal opacities) the success rate (IOP <21mmHg 
without complication and further surgery) was 17% at 13 months of follow up. (Al-Haddad 
et al., 2007). The authors attributed the poor results to the surgical difficulties of refractory 
pediatric glaucoma. Lima et al (Lima et al., 2004) compared ECP to Ahmed Valve 
implantation in 6\8 patients and found a success rate of 73.5% vs 70.6% (p = 0.7) 
respectively (mean follow up of 21.3 and 19.8 months respectively). Complications were 
different: ECP reported more cases of hypotony, phthisis, anterior segment inflammation, 
while Ahmed valve reported more cases of endophthalmitis, choroidal detachment and  
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 STUDY GLAUCOMA 
F-UP 
(mo) 
N 
(eyes) 
VA LOSS 
(%) 
N. 
TREAT 
DEGREES 
SUCCESS 
(%) 
Lima et al., 2004 all 21,3 68 9 1 210 73,5 
Yip et al., 2009 all 15,9 29 17 1 270 48,3 
Kahook et al., 2007 (1 site) all 4,5 15 0 1 240-300 47 
IOP reduction of 3 mmHg at least; 1 medication 
Kahook et al., 2007 (2 
sites) 
all 4,5 25 0 1 240-300 92 
IOP reduction of 3 mmHg at least; 1 medication 
Al-Haddad et al., 2007 pediatric 13,0 12 8 1,17 270 17 IOP<=21; 
Carter et al., 2007 
aphakic and 
pseudophakic 
children 
12 34 N/A 1,8 180-270 53 IOP<24; 
Murty et al., 2009 all 12,3 50 22 N/A 270-360 82,9 
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retinal detachment. Kahook et al (Kahook et al., 2007) compared 2-incision ECP to 1-incision 
ECP, finding a success rate of 92% for 2-incision vs. 47% for 1-incision. No major 
complications have been reported.  
5. Personal considerations and role of anti-VEGF and panfotocoagulation 
We personally have experience with cyclocryotherapy, contact diode TSCP and ciliary 
ablation with ultrasound. We long ago abandoned the US ciliary ablation due to the 
difficulties of the treatment and some serious adverse events related to the difficulty of 
centering the ultrasound beam exactly on the ciliary body. We are not using anymore 
cyclocryotherapy mainly because of the inflammatory processes related to this method. 
Inflammatory processes might be present with diode laser TSCP as well if the treatment is 
not titrated. We are very concerned of possible adverse events related to cycloddestruction 
and with the diode laser we prefer to stay on the safe side at the eventual price of 
retreatment rather than risk serious complications. Our current protocol with the diode laser 
is to treat 180 degrees using the G-probe. The time is pre-set at 2 seconds and we generally 
start with a 1800 mW power. We increase the power until a bob can be appreciated and then 
we decrease the power by 100 mW and we continue the treatment. We pay a lot of attention 
to keep the probe strongly pressed on the globe in order to achieve a better conduction 
through the sclera. The number of applications is titrated on the basis of the IOP level and 
on the type of glaucoma. We generally give more applications if the IOP is elevated with the 
exception of uveitic and neovascular glaucoma where we never apply as first treatment 
more than 14 applications, because we fear that in this forms of secondary glaucoma there 
might coexist a lower acqueous production. Concerning the use of anti-VEGF, Although 
there are several reports that claim a resolution of IOP elevation, we cannot confirm these 
findings. Probably the patients that come to our Department present long standing forms of 
iris neovascularisation. Although some of our patients did not present a complete angle 
occlusion at gonioscopy, we never had a complete normalization of IOP by using 
intravitreal injections. In a few cases intravitreal ant-VEGF injection, nevertheless, allowed 
for a partial recovery of the glaucoma with some clearing of the cornea, which allowed us 
for starting a pan-retinal photocoagulation. Retinal cryotherapy is always added whenever 
the panretinal photocoagulation is impossible due to corneal decompensation, cataract or 
vitreous hemorrage. 
6. Summary 
Both 810 nm diode laser TSCPC and ECP are effective procedures for the treatment of 
refractory glaucoma. TSCPC is an extra-ocular procedure that has mainly been used in eyes 
that had received prior filtration surgeries or that had very limited visual potential. 
However, more recently, there has been a trend toward using 810 nm diode laser TSCPC as 
the primary surgery in eyes with relatively good vision. ECP is an intra-ocular surgery that 
has also been used as a primary procedure, often combined with phacoemulsification 
cataract extraction, but should probably be considered almost exclusively in eyes that have 
good potential vision. These relative indications for each type of CPC are guided by the 
possible complications of each procedure. TSCPC is a “blind” procedure that has significant 
rates of success, but also hypotony and/or phthisis, which may relate to its external 
approach. Greater energy is generally required to penetrate the sclera as compared with the  
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 STUDY PROCEDURE GLAUCOMA F-UP (mo) 
N 
(eyes) 
VA LOSS 
(%) 
N. 
TREAT 
POWER 
(J) 
DEGREES 
Yildirim et al., 2009 TCP diode vs neovascular 24 33 18 1 >1,5  270 
Yildirim et al., 2009 ahmed valve neovascular 24 33 27 N/A N/A N/A 
Malik et al., 2006 TCP diode vs all 35 28 46 2 1,75 - 2,5 360 
Malik et al., 2006 molteno tube all 35 26 54 N/A N/A N/A 
Sood et al., 2009 TCP diode vs pediatric 19,8 9 20 1 1 - 1,5 180-270 
Sood et al., 2009 ahmed valve pediatric 26,3 8 75 N/A N/A N/A 
Agarwal et al., 2004 
C TCP diode 
830 nm vs. 
all 15,8 30 6 1,2 1,5 360 
Agarwal et al., 2004 
NC TCPdiode 
830 nm 
all 15,8 30 6 1,6 1,5 360 
Youn et al., 1998 TCP YAG vs. all 10,4 46 0 1,13 5,21 - 7,5  360 
Youn et al., 1998 TCP diode all 10,4 49 8 1,2 1,75 - 3 360 
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endoscopic approach. EPC allows the photocoagulation of the ciliary processes under direct 
visualization, but can also lead to the overtreatment of the ciliary tissues and surrounded 
structures, including the vascular structure of ciliary process, the pars plana, and the iris 
root, all of which may potentially predispose to phthisis or hypotony. The major 
disadvantage of ECP is that it is an intra-ocular procedure. Endophthalmitis, choroidal 
haemorrhage, and retinal detachment are rare, but remain potential serious complications. 
New transscleral 810 nm laser applications over the pars plana with a new micropulse laser 
emission mode, have been reported to result in effective IOP lowering, while avoiding most 
collateral problems of 810 nm continuous wave diode laser TSCPC and EPC (Tan et al., 
2010). 
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